Drug intelligence / Profile preview

BCG020

Development stage
Unknown
Lead developer
Biocytogen
Modality
Antibody-Based Therapeutics
01

Overview

BCG020: sourced facts only. name: "To explore this strategy, we developed a novel IgG1 bsAb, BCG020, targeting EGFR and CD70." [DOI:10.1158/1538-7445.am2024-2724]; target: "To explore this strategy, we developed a novel IgG1 bsAb, BCG020, targeting EGFR and CD70." [DOI:10.1158/1538-7445.am2024-2724]; target: "To explore this strategy, we developed a novel IgG1 bsAb, BCG020, targeting EGFR and CD70." [DOI:10.1158/1538-7445.am2024-2724]; developer: "1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China." [DOI:10.1158/1538-7445.am2024-2724]; modality: "To explore this strategy, we developed a novel IgG1 bsAb, BCG020, targeting EGFR and CD70." [DOI:10.1158/1538-7445.am2024-2724]; stage: "We observed that BCG020 treatment (10 mg/kg) potently inhibited growth of EGFR+CD70+ tumors." [DOI:10.1158/1538-7445.am2024-2724]

02

Targets

CD70 (Cluster of Differentiation 70)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on BCG020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCG020.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call